units for the production and preparation of dialysis water, concentrates and accessories
לפידות מדיקל יבוא ושיווק בע"מ - צוות טכני
פלומיסט קואדריוואלנט
astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.
mikro-tip catheter pressure transducer & control unit
מירום מיכשור לרפואה ומחקר בע"מ - רופא - מדידת לחץ פולשנית בבני-אדם או בחיות
אנהרטו
astrazeneca (israel) ltd - trastuzumab deruxtecan - אבקה להכנת תמיסה מרוכזת לעירוי - trastuzumab deruxtecan 100 mg - trastuzumab
לינפארזה 50 מג
astra zeneca (israel) ltd - olaparib - קפסולה קשיחה - olaparib 50 mg - olaparib
אונגלייזה 5 מג
astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
אונגלייזה 2.5 מג
astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
ביידוריון 2 מג
astrazeneca (israel) ltd - exenatide - אבקה וממס להכנת תרחיף להזרקה - exenatide 2 mg - exenatide - exenatide - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • metformin• sulphonylurea• metformin and sulphonylureain adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.
אירסה
astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.
פסלודקס
astrazeneca (israel) ltd - fulvestrant - תמיסה להזרקה - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - faslodex is indicated for the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antioestrogen therapy or disease progression on therapy with an antioestrogen.